



# Genasys Inc.

*Q2 upside. Large backlog and major contract wins/new product releases should drive strong growth. Lowering P/T to \$7.50.*

## COMPANY UPDATE

**Rating: BUY**

Ticker: GNSS

Price: \$2.99

Target: \$7.50  
(from \$8.00)

**Q2 upside:** Revenue was \$13 million (+17% y-o-y), compared with our and consensus estimates of \$12 million. EPS was \$(0.01), compared with our estimates of \$(0.05) and consensus of \$(0.04). There was no Q2 guidance.

**Solid backlog:** The company had solid growth in all products and many new customer wins (Slovenia and in the U.S. with first governments customers in Colorado, Oregon, and Kentucky). Backlog decreased to \$23 million vs. \$31 million last quarter.

**Guidance for FY22 revenue growth, but continued supply chain issues:** Management continues to expect revenue growth in FY22, but did state that there was more risk now due to ongoing supply chain issues with inventory shortages and higher prices.

**Maintaining estimates:** We are maintaining our FY22 estimates for revenue of \$52 million, and for EPS of \$(0.11). We are maintaining our FY23 estimates for revenue of \$57 million, and for EPS of \$0.08.

**Solid momentum:** The company has experienced strong revenue growth the past five years (+24% in FY17, +30% in FY18, +41% in FY19, +16% in FY20, and +9% in FY21). The management team has done a good job developing LRAD's core legacy Acoustic Hailing Devices (AHDs) and its newer Mass Notifications systems. This has helped win new product contracts and expand its customer base, and returning the company to strong growth.

**FY22 year of investment:** The company plans for significant investment in its business as operating expenses are expected to increase \$9 – 11 million versus FY21 operating expenses of \$22 million. The company is investing heavily in its SAAS business as it grows beyond its historical pure hardware business. It also expects to invest heavily in its sales and marketing areas.

**Zonehaven acquisition positive:** In June 2021, Genasys acquired Zonehaven, a fast-growing provider of SaaS solutions for emergency evacuations for \$24 million. The company continues to opportunistically pursue M&A opportunities.

**Positive momentum:** FY18 revenue growth was +30% (y-o-y), FY19 +41%, FY20 +16%, and FY21 was +9%. We believe and estimate this trend will continue into FY22 (+11%E) and FY23 (+10%E).

**Large market potential:** We believe there is substantial market demand for Genasys's products due to high government needs for improved communications as well as demands from the public for public safety communications and the high value and technology of the communication products that Genasys designs and manufactures.

**Valuation positive:** We are maintaining our BUY rating, but lowering our 12-month price target to \$7.50 from \$8.00, which is based on a forward P/E multiple of 30x our FY24 EPS estimate of \$0.25. We believe this multiple is reasonable as it is its estimated near-term earnings growth rate (implying a PEG ratio of ~1 (P/E to growth rate)). We believe this valuation appropriately balances out the company's risks with the company's growth prospects and large upside opportunities.

### Company Description

Based in San Diego, CA, Genasys designs and develops proprietary sound technologies and products that are deployed by the military, public safety, and commercial organizations around the world.

United States  
Technology

May 14, 2022

Edward Woo, CFA  
(949) 259-4932  
ewoo@ascendant.com

### Stock Data

Exchange:	NasdaqCM
52-week Range:	\$2.40 – 6.25
Shares Outstanding (million):	36
Market cap (\$million):	\$108
EV (\$million):	\$92
Debt (\$million):	\$0
Cash (\$million):	\$16
Avg. Daily Trading Vol. (\$million):	\$0.4
Float (million shares):	29
Short Interest (million shares):	0.2
Dividend, annual (yield):	\$0 (NA%)

### Revenues (US\$ million)

	<u>2022E</u> (Cur.)	<u>2022E</u> (Old)	<u>2023E</u> (Cur.)	<u>2023E</u> (Old)
Q1 Dec	11A		12E	
Q2 Mar	13A	12E	15E	13E
Q3 Jun	13E	14E	14E	15E
Q4 Sep	<u>16E</u>		<u>17E</u>	
Total	<b>52E</b>		<b>57E</b>	
EV/Revs	1.8x		1.6x	

### Earnings per Share (pro forma)

	<u>2022E</u> (Cur.)	<u>2022E</u> (Old)	<u>2023E</u> (Cur.)	<u>2023E</u> (Old)
Q1 Dec	(0.04)A		(0.03)E	
Q2 Mar	(0.01)A	(0.05)E	0.01E	
Q3 Jun	(0.03)E		0.03E	0.04E
Q4 Sep	<u>(0.03)E</u>	<u>0.00E</u>	<u>0.06E</u>	
Total	<b>(0.11)E</b>		<b>0.08E</b>	
P/E	N/A		37x	

### Important Disclosures

Ascendant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

**For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 7.**

### **OVERVIEW**

- Genasys recently (on May 9) reported its fiscal Q2 FY22 (ending March) results.
- Revenue was \$13 million (+17% y-o-y), compared with our and consensus estimates of \$12 million.
- EPS was \$(0.01), compared with our estimates of \$(0.05) and consensus of \$(0.04).
- There was no Q2 guidance.
- Management as usual did not provide any specific forward guidance, but qualitatively continues to expect revenue growth in FY22.
- We are maintaining our FY22 estimates for revenue of \$52 million, and for EPS of \$(0.11).
- We are maintaining our FY23 estimates for revenue of \$57 million, and for EPS of \$0.08.

### **ADDITIONAL DETAILS**

- Gross profit for the quarter was \$7 million, compared with our estimate of \$6 million.
- Gross margin for the quarter was 53%, versus 47% last year and our estimate of 50%.
- Operating expenses were \$8 million, compared with our estimate of \$8 million.
- Operating loss was \$0.5 million, compared with our estimate of a loss of \$1.9 million.
- Net loss was \$0.5 million, compared with our estimate of a loss of \$1.7 million.
- Backlog was \$24 million vs. \$31 million last quarter.
  
- In January 2018, LRAD announced the acquisition of Genasys Holding S.L., a leading software provider of advanced location-based mass messaging solutions for emergency warning systems and workforce management. Genasys, based in Madrid, Spain, had 2017 revenues of ~\$2.3 million. The purchase price was ~\$3 million.
- In October 2019, LRAD rebranded as Genasys Inc. to reflect its broader commitment to critical communications.
- In August 2020, Genasys announced that it will acquire privately held Amika Mobile, a Canada-based enterprise software provider of critical event situational awareness, communication and control products. The purchase price was ~\$8 million. The deal closed in October 2020.
- In June 2021, Genasys acquired Zonehaven, a fast-growing provider of software-as-a-service (SaaS) solutions for emergency evacuations. Based in San Francisco, CA, Zonehaven's services are trusted by more than 170 fire districts, 140 law enforcement agencies and 200 cities, with more than 3,300 evacuation zones covering 3.2 million people in Northern California and Southern Oregon. The purchase price was \$24 million in cash and stock.

The company's balance sheet is solid with \$16 million in cash and no debt, compared with \$18 million in cash and no debt as of December.

**Exhibit 1: Genasys Inc. Stock Price (5-Years)**



Source: <https://bigcharts.marketwatch.com/>

**Exhibit 2: Consensus Expectations (as of May 9, 2022)**

	Revenue (mil)			EPS	
	2022E	2023E		2022E	2023E
Q1 Dec	\$11A		Q1 Dec	\$(0.04)A	
Q2 Mar	\$12E		Q2 Mar	\$(0.04)E	
Q3 Jun	\$14E		Q3 Jun	\$(0.03)E	
Q4 Sep			Q4 Sep		
Total	\$53E	\$61E	Total	\$(0.10)E	\$0.03E

\*Quarterly estimates may not add to annual estimates due to variations in contributing estimates and rounding.

Source: Company report, Refinitiv, and Ascendant Capital Markets estimates

## FINANCIAL MODEL

### Genasys Inc.

Income Statement (\$ mils)	Dec-19	Mar-20	Jun-20	Sep-20	2020	Dec-20	Mar-21	Jun-21	Sep-21	2021	Dec-21	Mar-22	Jun-22	Sep-22	2022	Dec-22	Mar-23	Jun-23	Sep-23	2023
Fiscal Year End: September 30	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Product sales	8.8	8.3	12.0	14.0	43.0	8.0	11.3	12.6	15.0	47.0	10.7	13.2	12.8	15.7	52.3	11.7	14.5	13.7	17.4	57.4
Contract and other					0.0					0.0					0.0					0.0
<b>Total Revenue</b>	<b>8.8</b>	<b>8.3</b>	<b>12.0</b>	<b>14.0</b>	<b>43.0</b>	<b>8.0</b>	<b>11.3</b>	<b>12.6</b>	<b>15.0</b>	<b>47.0</b>	<b>10.7</b>	<b>13.2</b>	<b>12.8</b>	<b>15.7</b>	<b>52.3</b>	<b>11.7</b>	<b>14.5</b>	<b>13.7</b>	<b>17.4</b>	<b>57.4</b>
<u>Cost of Revenues</u>	<u>4.2</u>	<u>4.3</u>	<u>5.5</u>	<u>6.4</u>	<u>20.4</u>	<u>4.3</u>	<u>6.0</u>	<u>5.9</u>	<u>7.3</u>	<u>23.6</u>	<u>5.8</u>	<u>6.2</u>	<u>6.4</u>	<u>7.9</u>	<u>26.2</u>	<u>5.3</u>	<u>6.1</u>	<u>5.4</u>	<u>6.4</u>	<u>23.2</u>
Gross Profit	4.6	4.0	6.5	7.6	22.6	3.7	5.3	6.7	7.7	23.4	4.9	7.0	6.4	7.9	26.1	6.5	8.4	8.4	11.0	34.2
Selling, general and administrative	2.8	2.7	3.3	3.2	12.0	3.3	3.8	4.8	5.5	17.4	5.1	5.6	5.7	6.9	23.4	5.5	5.5	5.2	6.4	22.7
Research and development	1.1	0.9	1.2	1.3	4.6	1.1	1.0	1.4	1.5	4.9	1.4	1.9	1.8	2.2	7.2	2.2	2.3	1.8	2.1	8.4
Restructuring and other					0.0					0.0					0.0					0.0
Total operating expenses	3.9	3.7	4.5	4.5	16.6	4.4	4.8	6.2	7.0	22.3	6.5	7.5	7.5	9.1	30.6	7.8	7.8	7.0	8.5	31.1
<b>Operating income (loss)</b>	<b>0.7</b>	<b>0.3</b>	<b>1.9</b>	<b>3.1</b>	<b>6.0</b>	<b>(0.7)</b>	<b>0.6</b>	<b>0.5</b>	<b>0.7</b>	<b>1.1</b>	<b>(1.6)</b>	<b>(0.5)</b>	<b>(1.1)</b>	<b>(1.3)</b>	<b>(4.5)</b>	<b>(1.3)</b>	<b>0.6</b>	<b>1.4</b>	<b>2.4</b>	<b>3.1</b>
Interest income (expense)	0.1	0.1	0.0	(0.1)	0.1	0.1	(0.0)	(0.0)	(0.0)	0.1	0.0	(0.0)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other income (expense)					0.0					0.0	0.3				0.3					0.0
Income before income taxes	0.8	0.4	2.0	3.0	6.2	(0.6)	0.5	0.5	0.7	1.1	(1.3)	(0.5)	(1.1)	(1.3)	(4.2)	(1.3)	0.6	1.4	2.4	3.1
Income taxes	0.2	0.1	0.5	(6.4)	(5.7)	(0.0)	0.3	0.2	(0.1)	0.4		(0.0)	(0.1)	(0.1)	(0.3)	(0.1)	0.1	0.1	0.2	0.3
Net income (loss)	0.6	0.3	1.5	9.4	11.9	(0.6)	0.3	0.3	0.8	0.7	(1.3)	(0.5)	(1.0)	(1.1)	(4.0)	(1.2)	0.5	1.2	2.2	2.8
<u>Nonrecurring/noncash adjustments</u>					0.0					0.0					0.0					0.0
<b>Net income (pro forma)</b>	<b>0.6</b>	<b>0.3</b>	<b>1.5</b>	<b>9.4</b>	<b>11.9</b>	<b>(0.6)</b>	<b>0.3</b>	<b>0.3</b>	<b>0.8</b>	<b>0.7</b>	<b>(1.3)</b>	<b>(0.5)</b>	<b>(1.0)</b>	<b>(1.1)</b>	<b>(4.0)</b>	<b>(1.2)</b>	<b>0.5</b>	<b>1.2</b>	<b>2.2</b>	<b>2.8</b>
EBITDA	1.2	1.0	2.6	3.0	7.8	(0.2)	1.2	1.4	1.8	4.1	(0.4)	0.9	0.2	0.1	0.8	0.1	2.0	2.8	3.8	8.6
Shares, Basic	33.0	33.1	33.3	33.5	33.2	33.6	33.7	34.1	36.2	34.4	36.5	36.4	36.6	36.7	36.5	36.8	36.9	37.1	37.2	37.0
Shares, Diluted	33.7	33.7	34.3	34.6	34.1	34.7	34.8	35.3	37.3	35.6	36.5	36.4	36.6	36.7	36.5	36.8	36.9	37.1	37.2	37.0
EPS Basic (Pro forma)	\$0.02	\$0.01	\$0.05	\$0.28	\$0.36	(\$0.02)	\$0.01	\$0.01	\$0.02	\$0.02	(\$0.04)	(\$0.01)	(\$0.03)	(\$0.03)	(\$0.11)	(\$0.03)	\$0.01	\$0.03	\$0.06	\$0.08
<b>EPS Diluted (Pro forma)</b>	<b>\$0.02</b>	<b>\$0.01</b>	<b>\$0.04</b>	<b>\$0.27</b>	<b>\$0.35</b>	<b>(\$0.02)</b>	<b>\$0.01</b>	<b>\$0.01</b>	<b>\$0.02</b>	<b>\$0.02</b>	<b>(\$0.04)</b>	<b>(\$0.01)</b>	<b>(\$0.03)</b>	<b>(\$0.03)</b>	<b>(\$0.11)</b>	<b>(\$0.03)</b>	<b>\$0.01</b>	<b>\$0.03</b>	<b>\$0.06</b>	<b>\$0.08</b>
<b>Margins</b>																				
Gross margin	52.4%	48.5%	54.1%	54.0%	52.6%	46.1%	47.2%	53.0%	51.2%	49.8%	45.8%	52.9%	50.0%	50.0%	49.9%	55.0%	58.0%	61.0%	63.0%	59.6%
Selling, general and administrative	32.1%	33.0%	27.8%	22.6%	28.0%	41.5%	33.8%	37.8%	36.5%	37.1%	48.1%	42.5%	45.0%	44.0%	44.7%	47.0%	38.0%	38.0%	37.0%	39.5%
Research and development	12.3%	11.5%	10.0%	9.4%	10.6%	13.3%	8.5%	11.0%	10.0%	10.5%	12.8%	14.4%	14.0%	14.0%	13.9%	19.0%	16.0%	13.0%	12.0%	14.7%
Operating margin	7.9%	4.0%	16.2%	22.0%	14.0%	-8.6%	4.9%	4.1%	4.7%	2.3%	-15.1%	-4.0%	-9.0%	-8.0%	-8.7%	-11.0%	4.0%	10.0%	14.0%	5.4%
Tax rate, GAAP	21.7%	24.3%	23.9%	-214.9%	-92.5%	0.8%	51.9%	44.0%	-10.3%	38.1%	0.0%	8.4%	10.0%	10.0%	6.7%	10.0%	10.0%	10.0%	10.0%	10.0%
Net margin	7.1%	3.6%	12.6%	67.6%	27.6%	-7.7%	2.3%	2.3%	5.1%	1.5%	-12.2%	-3.7%	-8.1%	-7.2%	-7.6%	-9.9%	3.6%	9.0%	12.6%	4.9%
<b>YY % change</b>																				
Total Revenue	-14%	-19%	35%	80%	16%	-9%	37%	5%	8%	9%	33%	17%	1%	4%	11%	10%	10%	8%	11%	10%
Gross margin	-10%	-23%	41%	111%	23%	-20%	33%	3%	2%	3%	32%	30%	-5%	2%	11%	32%	21%	31%	39%	31%
Selling, general and administrative	3%	10%	23%	11%	12%	18%	40%	43%	74%	45%	54%	46%	20%	26%	34%	8%	-2%	-9%	-7%	-3%
Research and development	3%	-26%	0%	32%	1%	-2%	1%	16%	14%	8%	28%	97%	28%	47%	47%	63%	22%	0%	-5%	16%
Operating income (loss)	-46%	-77%	183%	-1218%	93%	-200%	68%	-73%	-77%	-82%	132%	-195%	-321%	-279%	-519%	-20%	-210%	-220%	-294%	-168%
Net income (loss)	-41%	-74%	136%	-12213%	326%	-200%	-13%	-81%	-92%	-94%	111%	-288%	-456%	-247%	-663%	-11%	-206%	-220%	-294%	-170%
EPS Diluted (Pro forma)	-41%	-75%	129%	-11551%	318%	-197%	-16%	-81%	-92%	-94%	101%	-280%	-444%	-249%	-649%	-12%	-205%	-218%	-291%	-169%

Source: Company reports and Ascendant Capital Markets estimates.

**Genasys Inc.**

Balance Sheet (\$ mils)	Dec-19	Mar-20	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23
Fiscal Year End: September 30	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
<b>Assets</b>																
Cash and cash equivalents	17.1	16.4	20.7	23.3	19.6	18.5	14.5	13.2	10.1	9.0	9.8	1.7	8.5	7.1	14.7	10.0
Short term investments	4.2	3.5	4.1	4.3	5.5	5.5	6.0	5.7	3.9	5.2	5.2	5.2	5.2	5.2	5.2	5.2
Accounts receivable, net	5.9	5.8	6.4	5.4	3.2	5.4	6.3	7.7	6.8	5.6	7.4	11.9	5.9	8.2	7.9	13.2
Inventory	6.1	6.9	7.3	5.9	7.0	6.5	6.4	6.4	9.1	9.6	9.6	11.8	9.2	11.1	8.0	9.7
Deferred income taxes											0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses and other	1.3	1.3	1.3	6.3	1.0	1.4	1.8	2.5	1.5	1.7	1.9	2.1	2.1	1.8	2.1	2.3
<b>Total current assets</b>	<b>34.6</b>	<b>33.9</b>	<b>39.8</b>	<b>45.3</b>	<b>36.2</b>	<b>37.2</b>	<b>35.0</b>	<b>35.5</b>	<b>31.5</b>	<b>31.1</b>	<b>33.9</b>	<b>32.7</b>	<b>30.9</b>	<b>33.3</b>	<b>37.9</b>	<b>40.3</b>
Long term securities/investments	1.3	1.6	3.3	3.8	3.6	3.6	3.5	1.9	3.4	2.3	2.3	2.3	2.3	2.3	2.3	2.3
Property and equipment, net	2.2	2.1	2.0	1.9	1.9	1.9	1.8	1.8	1.8	1.7	1.4	1.0	0.7	0.4	0.0	(0.3)
Intangibles, net	3.5	3.4	3.4	3.4	12.2	12.0	37.3	36.6	36.0	35.6	35.6	35.6	35.6	35.6	35.6	35.6
Deferred income tax	5.2	5.1	4.6	11.1	11.1	10.8	10.7	8.0	8.3	8.4	8.4	8.4	8.4	8.4	8.4	8.4
Other	5.8	6.1	5.9	5.8	5.5	5.4	5.2	6.3	6.2	6.0	6.0	6.0	6.0	6.0	6.0	6.0
<b>Total assets</b>	<b>52.6</b>	<b>52.2</b>	<b>59.0</b>	<b>71.4</b>	<b>70.6</b>	<b>70.9</b>	<b>93.6</b>	<b>90.1</b>	<b>87.3</b>	<b>85.1</b>	<b>87.5</b>	<b>85.9</b>	<b>83.8</b>	<b>85.9</b>	<b>90.1</b>	<b>92.2</b>
<b>Liabilities and stockholders' equity</b>																
Accounts payable	1.5	1.9	2.9	1.4	1.6	2.6	2.7	2.2	2.3	3.0	5.6	2.3	4.3	3.2	6.0	2.6
Accrued expenses	6.3	5.4	8.9	13.1	7.8	7.0	13.3	14.1	12.6	10.2	8.9	11.0	8.2	10.1	9.6	12.2
Deferred revenue											0.0	0.0	0.0	0.0	0.0	0.0
Deferred income tax											0.0	0.0	0.0	0.0	0.0	0.0
Other	0.7	0.7	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.0	0.0	0.0	0.0
Short term debt	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
<b>Total current liabilities</b>	<b>8.8</b>	<b>8.4</b>	<b>12.8</b>	<b>15.5</b>	<b>10.6</b>	<b>10.7</b>	<b>17.2</b>	<b>17.5</b>	<b>16.1</b>	<b>14.3</b>	<b>15.6</b>	<b>14.5</b>	<b>12.8</b>	<b>13.6</b>	<b>15.8</b>	<b>15.0</b>
Deferred income taxes											6.3	6.3	6.3	6.3	6.3	6.3
Other long term liabilities	7.4	7.2	7.0	6.7	7.3	7.1	11.4	6.7	6.5	6.3	6.3	6.3	6.3	6.3	6.3	6.3
Long term debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Total other liabilities</b>	<b>7.5</b>	<b>7.2</b>	<b>7.0</b>	<b>6.7</b>	<b>7.3</b>	<b>7.1</b>	<b>11.4</b>	<b>6.7</b>	<b>6.5</b>	<b>6.3</b>	<b>6.3</b>	<b>6.3</b>	<b>6.3</b>	<b>6.3</b>	<b>6.3</b>	<b>6.3</b>
Common stock	0.0	0.0	0.0	0.0							0.7	1.5	2.2	2.9	3.7	4.4
Additional paid-in capital	89.9	89.8	90.9	91.2	94.9	95.2	106.6	107.1	107.3	107.5	107.5	107.5	107.5	107.5	107.5	107.5
Retained earnings	(53.1)	(52.8)	(51.3)	(41.9)	(42.5)	(42.2)	(41.9)	(41.2)	(42.5)	(43.0)	(44.0)	(45.1)	(46.3)	(45.8)	(44.5)	(42.3)
Accumulated other comprehensive in	(0.4)	(0.4)	(0.4)	(0.3)	0.2	0.1	0.3	0.0	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Other	(0.0)										1.4	1.4	1.4	1.4	1.4	1.4
<b>Total stockholders' equity</b>	<b>36.4</b>	<b>36.6</b>	<b>39.2</b>	<b>49.1</b>	<b>52.7</b>	<b>53.1</b>	<b>65.0</b>	<b>66.0</b>	<b>64.7</b>	<b>64.5</b>	<b>65.5</b>	<b>65.1</b>	<b>64.7</b>	<b>66.0</b>	<b>67.9</b>	<b>70.9</b>
<b>Total stockholders' equity and liabil</b>	<b>52.6</b>	<b>52.2</b>	<b>59.0</b>	<b>71.4</b>	<b>70.6</b>	<b>70.9</b>	<b>93.6</b>	<b>90.1</b>	<b>87.3</b>	<b>85.1</b>	<b>87.5</b>	<b>85.9</b>	<b>83.8</b>	<b>85.9</b>	<b>90.1</b>	<b>92.2</b>

**Balance Sheet Drivers**

	Dec-19	Mar-20	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23
	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Prepaid as % of total rev	15%	15%	11%	45%	13%	12%	14%	17%	14%	13%	15%	13%	18%	12%	15%	13%
Accounts payable as % of total rev	17%	23%	24%	10%	20%	23%	21%	14%	21%	22%	44%	15%	37%	22%	44%	15%
Inventories as % of cost of rev	145%	162%	133%	93%	161%	108%	108%	87%	158%	155%	150%	150%	175%	182%	150%	150%
Accrued expenses as % of total rev	72%	66%	74%	94%	98%	62%	105%	94%	118%	77%	70%	70%	70%	70%	70%	70%
<b>Activity Ratios</b>																
A/R Days Sales Outstanding	61	64	48	35	35	43	45	46	57	38	52	68	45	51	52	68
Inventory Turnover	2.8x	2.5x	3.0x	4.3x	2.5x	3.7x	3.7x	4.6x	2.5x	2.6x	2.7x	2.7x	2.3x	2.2x	2.7x	2.7x
A/P Days Payable	32	41	48	19	34	39	41	26	35	43	78	27	73	48	100	36
<b>Book &amp; Cash Value (per share)</b>																
Book Value per Share (diluted)	\$1.08	\$1.08	\$1.14	\$1.42	\$1.52	\$1.53	\$1.84	\$1.77	\$1.78	\$1.77	\$1.79	\$1.78	\$1.76	\$1.79	\$1.83	\$1.91
Cash per Share (diluted)	\$0.67	\$0.64	\$0.82	\$0.91	\$0.83	\$0.79	\$0.68	\$0.56	\$0.48	\$0.45	\$0.47	\$0.25	\$0.43	\$0.40	\$0.60	\$0.47
Net cash per Share (diluted)	\$0.66	\$0.63	\$0.81	\$0.90	\$0.82	\$0.78	\$0.67	\$0.55	\$0.47	\$0.45	\$0.47	\$0.24	\$0.43	\$0.39	\$0.59	\$0.46

Source: Company reports and Ascendant Capital Markets estimates

**Genasys Inc.**


Cash Flow Statement (\$ mils)	Dec-19	Mar-20	Jun-20	Sep-20	2020	Dec-20	Mar-21	Jun-21	Sep-21	2021	Dec-21	Mar-22	Jun-22	Sep-22	2022	Dec-22	Mar-23	Jun-23	Sep-23	2023
Fiscal Year End: September 30	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
<b>Cash flow from operating activities</b>																				
Net income	0.6	0.3	1.5	9.4	11.9	(0.6)	0.3	0.3	0.8	0.7	(1.3)	(0.5)	(1.0)	(1.1)	(4.0)	(1.2)	0.5	1.2	2.2	2.8
Depreciation	0.2	0.2	0.2	0.2	0.8	0.3	0.3	0.4	0.6	1.6	0.6	0.6	0.6	0.6	2.6	0.6	0.6	0.6	0.6	2.6
Amortization	0.1	0.1	0.2	(0.4)	0.0	0.2	(0.2)	0.0	0.0	0.0	0.0	0.4		0.4						0.0
Stock comp	0.2	0.3	0.3	0.2	1.0	0.2	0.3	0.4	0.5	1.4	0.6	0.7	0.7	0.7	2.8	0.7	0.7	0.7	0.7	2.9
Provision for bad debts				0.0	0.0					0.0					0.0					0.0
Deferred income taxes	0.2	0.1	0.5	(6.5)	(5.7)	(0.0)	0.3	0.3	(0.1)	0.4	(0.3)	(0.0)	0.0	0.0	(0.3)	0.0	0.0	0.0	0.0	0.0
Warranty provision	(0.0)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0		0.0						0.0
Inventory obsolescence	0.1	0.0	0.0	0.2	0.4	0.1	0.1	0.1	0.1	0.4	0.0	0.0		0.1						0.0
Other gains/losses				0.1	0.1	(0.1)	0.0	(0.0)		(0.1)				0.0						0.0
Other				0.6	0.6		0.4	0.2	0.2	0.7	0.2	(0.2)		0.0						0.0
<b>Changes in operating assets and liabilities:</b>																				
Accounts receivable	(2.3)	0.1	(0.5)	0.9	(1.8)	2.3	(2.3)	(0.6)	(1.6)	(2.1)	0.9	1.2	(1.8)	(4.5)	(4.2)	6.0	(2.3)	0.3	(5.3)	(1.3)
Inventory	(0.3)	(0.9)	(0.5)	1.1	(0.5)	(1.1)	0.4	(0.1)	(0.1)	(0.8)	(2.8)	(0.5)	0.1	(2.2)	(5.4)	2.5	(1.8)	3.1	(1.6)	2.1
Prepaid expenses & other curre	0.8	0.0	(0.1)	0.2	0.9	0.1	(0.4)	(0.4)	(1.0)	(1.6)	1.0	(0.2)	(0.2)	(0.2)	0.4	0.0	0.3	(0.3)	(0.2)	(0.2)
Other assets				0.0	0.0					0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	0.6	0.5	1.0	(1.6)	0.5	0.2	1.0	(0.1)	(0.5)	0.6	0.1	0.7	2.6	(3.2)	0.2	2.0	(1.1)	2.7	(3.4)	0.2
Accrued expenses	(1.9)	(1.1)	3.2	(1.4)	(1.2)	(0.3)	(1.0)	7.4	(1.1)	4.9	(1.7)	(2.7)	(1.2)	2.1	(3.6)	(2.8)	1.9	(0.5)	2.6	1.2
Warranty settlements				0.0	0.0					0.0					0.0					0.0
Deferred revenue				0.0	0.0					0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities				0.0	0.0					0.0			0.0	0.0	0.0	(0.9)	0.0	0.0	0.0	(0.9)
<b>Net cash (used in) provided by</b>	<b>(1.8)</b>	<b>(0.3)</b>	<b>5.8</b>	<b>3.2</b>	<b>6.9</b>	<b>1.3</b>	<b>(0.9)</b>	<b>8.0</b>	<b>(2.2)</b>	<b>6.2</b>	<b>(2.7)</b>	<b>(0.4)</b>	<b>(0.2)</b>	<b>(7.8)</b>	<b>(11.1)</b>	<b>7.0</b>	<b>(1.0)</b>	<b>7.8</b>	<b>(4.4)</b>	<b>9.5</b>
<b>Cash flow from investing activities</b>																				
Purchases of property and equip	(0.1)	(0.0)	(0.0)	(0.0)	(0.1)	(0.0)	(0.1)	(0.0)	(0.0)	(0.2)	(0.2)	(0.0)	(0.3)	(0.3)	(0.8)	(0.3)	(0.3)	(0.3)	(0.3)	(1.2)
Purchases of short-term investm	(0.1)	0.0	(2.3)	(0.7)	(3.0)	0.1	0.0	(0.3)	0.7	0.5	0.2	(0.2)			0.0					0.0
Acquisitions					0.0	(4.4)		(11.5)		(15.8)					0.0					0.0
Other					0.0					0.0					0.0					0.0
<b>Net cash used in investing activ</b>	<b>(0.1)</b>	<b>(0.0)</b>	<b>(2.3)</b>	<b>(0.7)</b>	<b>(3.1)</b>	<b>(4.3)</b>	<b>(0.1)</b>	<b>(11.9)</b>	<b>0.7</b>	<b>(15.6)</b>	<b>0.1</b>	<b>(0.2)</b>	<b>(0.3)</b>	<b>(0.3)</b>	<b>(0.7)</b>	<b>(0.3)</b>	<b>(0.3)</b>	<b>(0.3)</b>	<b>(0.3)</b>	<b>(1.2)</b>
<b>Cash flow from financing activities</b>																				
Issuance of debt					0.0					0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Repayment of debt		(0.0)	(0.0)	0.0	(0.0)		(0.1)	0.0	0.0	(0.1)		(0.0)			(0.0)					0.0
Issuance of stock					0.0					0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Repurchase of common stock		(0.4)			(0.4)					0.0	(0.4)	(0.6)			(1.0)					0.0
Proceeds from stock option exe	0.1	0.1	0.8	0.1	1.1	0.1	(0.0)	0.0	0.0	0.1	0.0	0.1			0.1					0.0
Other					0.0					0.0					0.0					0.0
Dividends and distributions					0.0					0.0					0.0					0.0
<b>Cash provided by (used in) fina</b>	<b>0.1</b>	<b>(0.3)</b>	<b>0.7</b>	<b>0.1</b>	<b>0.7</b>	<b>0.1</b>	<b>(0.1)</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>(0.4)</b>	<b>(0.5)</b>	<b>0.0</b>	<b>0.0</b>	<b>(0.9)</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>
Effect of exchange rate on cash	0.0	(0.0)	(0.0)	0.0	0.0	0.0	(0.0)	0.0	(0.1)	(0.1)	(0.0)	(0.0)			(0.0)					0.0
<b>Net increase (decrease) in cash</b>	<b>(1.8)</b>	<b>(0.7)</b>	<b>4.3</b>	<b>2.7</b>	<b>4.5</b>	<b>(2.9)</b>	<b>(1.1)</b>	<b>(3.9)</b>	<b>(1.5)</b>	<b>(9.5)</b>	<b>(3.0)</b>	<b>(1.2)</b>	<b>(0.5)</b>	<b>(8.1)</b>	<b>(12.8)</b>	<b>6.7</b>	<b>(1.3)</b>	<b>7.5</b>	<b>(4.7)</b>	<b>8.3</b>
<b>Beginning cash and equivalents</b>	<b>19.5</b>	<b>17.8</b>	<b>17.1</b>	<b>21.3</b>	<b>19.5</b>	<b>24.0</b>	<b>21.1</b>	<b>19.9</b>	<b>16.0</b>	<b>24.0</b>	<b>14.5</b>	<b>11.5</b>	<b>10.3</b>	<b>9.8</b>	<b>14.5</b>	<b>1.7</b>	<b>8.5</b>	<b>7.1</b>	<b>14.7</b>	<b>1.7</b>
<b>Ending cash and equivalents</b>	<b>17.8</b>	<b>17.1</b>	<b>21.3</b>	<b>24.0</b>	<b>24.0</b>	<b>21.1</b>	<b>19.9</b>	<b>16.0</b>	<b>14.5</b>	<b>14.5</b>	<b>11.5</b>	<b>10.3</b>	<b>9.8</b>	<b>1.7</b>	<b>1.7</b>	<b>8.5</b>	<b>7.1</b>	<b>14.7</b>	<b>10.0</b>	<b>10.0</b>

Source: Company reports and Ascendant Capital Markets estimates

## ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

## Genasys Inc.



Source: <https://bigcharts.marketwatch.com/>

	Report Date		Price
Report	Date	Rating	Target
1	1/16/2018	B	3.50
2	2/9/2018	B	3.50
3	5/16/2018	B	3.75
4	8/15/2018	B	4.00
5	8/23/2018	B	4.50
6	12/14/2018	B	4.00
7	2/17/2019	B	4.25
8	5/8/2019	B	4.50
9	8/13/2019	B	4.75
10	12/15/2019	B	4.50
11	2/11/2020	B	4.75
12	5/12/2020	B	5.50
13	8/11/2020	B	5.75
14	12/14/2020	B	8.50
15	2/13/2021	B	8.75
16	5/17/2021	B	9.00
17	8/7/2021	B	9.50
18	11/23/2021	B	8.50
19	3/2/2022	B	8.00

- Ascendant Capital Markets, LLC has not received compensation for investment banking services from the company in the past 12 months.

## IMPORTANT DISCLOSURES

This report has been distributed by Ascendant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation

to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendant Capital Markets, LLC.

## Risks & Considerations

Risks to attainment of our share price target include changes and demand for technology, investor sentiment for investing in technology stocks, and consumer sentiment and industry growth for technology manufacturing companies, competition, changing macroeconomic factors, and changes in government budgets and political priorities.

## Ascendant Capital Markets, LLC Rating System

**BUY:** We expect the stock to provide a total return of 15% or more within a 12-month period.

**HOLD:** We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

**SELL:** We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

## Ascendant Capital Markets, LLC Rating System

*Prior to January 31, 2014, ASCM used the following rating system:*

**Strong Buy:** We expect the stock to provide a total return of 30% or more within a 12-month period.

**Buy:** We expect the stock to provide a total return of between 10% and 30% within a 12-month period.

**Neutral:** We expect the stock to provide a total return of between minus 10% and plus 10% within a 12-month period.

**Sell:** We expect the stock to provide a total return of minus 10% or worse within a 12-month period.

**Speculative Buy:** This rating is reserved for companies we believe have tremendous potential, but whose stocks are illiquid or whose equity market capitalizations are very small, often in the definition of a nano cap (below \$50 million in market cap). In general, for stocks ranked in this category, we expect the stock to provide a total return of 50% or more within a 12-month period. However, because of the illiquid nature of the stock's trading and/or the nano cap nature of the investment, we caution that these investments may not be suitable for all parties.

Total return is defined as price appreciation plus dividend yield.



### Ascendant Capital Markets, LLC Distribution of Investment Ratings (as of April 17, 2022)

Rating	Count	Percent	Investment Banking Services Past 12 months	
			Count	Percent
Buy	41	98%	13	32%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	42	100%	13	31%

### Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

### Dissemination of Research

Ascendant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

### General Disclaimer

The information and opinions in this report were prepared by Ascendant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

### Additional Disclosures

Ascendant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.